Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Merck Halts Enrollment in Keytruda Clinical Trials Following Patient Deaths

XTALKS VITALS NEWS

Chemo

The decision was made based on an external data monitoring committee’s recommendation.

Share this!

June 15, 2017 | by Sarah Hand, M.Sc.

Merck has announced that they will not be enrolling any new patients into two Phase III clinical trials involving Keytruda (pembrolizumab) following reports of patient deaths. The decision was made based on an external data monitoring committee’s recommendation.

“The pause is to allow for additional information to be collected to better understand more reports of death in the Keytruda groups,” said Merck in a press release. “Patients currently enrolled in these two studies will continue to receive treatment.”

Both the KEYNOTE-183 and KEYNOTE-185 clinical trials were testing Keytruda treatment in combination with other therapies in patients with multiple myeloma. Keytruda has already been approved for a number of indications, including treatment of melanoma, lung cancer and Hodgkin lymphoma.



The KEYNOTE-183 clinical trial is assessing a combo treatment involving pomalidomide, low-dose dexamethasone and Keytruda. In addition to low-dose dexamethasone, the KEYNOTE-185 clinical trial is testing a combo of lenalidomide and Keytruda.

Keytruda is an anti-PD-L1 immunotherapy that supports the patient’s immune system in destroying cancer cells. The checkpoint inhibitor has not shown these types of safety issues in previous clinical trials.

The FDA recently approved Keytruda to treat patients whose cancer has the MSI-H biomarker, regardless of the tumor’s tissue of origin. The biomarker has been identified in multiple cancer types, including endometrial, colorectal and gastrointestinal tumors.


Keywords:  Clinical Trial, Keytruda, Multiple Myeloma


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Kite Pharma Secures FDA Approval for CAR-T Immunotherapy

October 20, 2017 - Kite Pharma’s Yescarta (axicabtagene ciloleucel) has become the second CAR-T immunotherapy to be approved in the US, with an indication in treating adult patients with relapsed or refractory large B-cell lymphoma.

Featured In: Biotech News


Fallopian Tubes Found to be Site of Origin for Most Ovarian Cancers

October 20, 2017 - This year, over 22,000 women will be diagnosed with ovarian cancer but a new study conducted by researchers at Perlmutter Cancer Center at NYU Langone Health suggests that most of these malignancies begin in another part of the reproductive system: the fallopian tubes.

Featured In: Life Science News


Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.